Database ID | HIV0001480 |
UniProt ID | Q92833 |
Primary gene name(s) | JARID2 |
Synonym gene name(s) | JMJ |
Protein name | Protein Jumonji |
Protein function | Regulator of histone methyltransferase complexes that plays an essential role in embryonic development, including heart and liver development, neural tube fusion process and hematopoiesis. Acts by modulating histone methyltransferase activity and promoting the recruitment of histone methyltransferase complexes to their target genes. Binds DNA and mediates the recruitment of the PRC2 complex to target genes in embryonic stem cells. Does not have histone demethylase activity but regulates activity of various histone methyltransferase complexes. In embryonic stem cells, it associates with the PRC2 complex and inhibits trimethylation of 'Lys-27' of histone H3, H3K27me3 by the PRC2 complex, thereby playing a key role in differentiation of embryonic stem cells and normal development. In cardiac cells, it is required to repress expression of cyclin-D1, CCND1 by activating methylation of 'Lys-9' of histone H3, H3K9me by the GLP1/EHMT1 and G9a/EHMT2 histone methyltransferases. Also acts as a transcriptional repressor of ANF via its interaction with GATA4 and NKX2-5. Participates in the negative regulation of cell proliferation signaling. {ECO:0000269|PubMed:20075857}. |
Subcellular location | Nucleus {ECO:0000255|PROSITE-ProRule:PRU00355, ECO:0000255|PROSITE-ProRule:PRU00537, ECO:0000269|PubMed:20075857}. Note=Colocalizes with the PRC2 complex on chromatin. |
ECO code | Click here for more information. |
Amino acid sequence FASTA format: Q92833 |
|
Gene Ontology (Biological Process) Complete annatation | central nervous system development [GO:0007417]; covalent chromatin modification [GO:0016569]; liver development [GO:0001889]; negative regulation of cell proliferation [GO:0008285]; negative regulation of gene expression, epigenetic [GO:0045814]; negative regulation of histone methylation [GO:0031061]; negative regulation of transcription, DNA-templated [GO:0045892]; positive regulation of histone H3-K9 methylation [GO:0051574]; spleen development [GO:0048536]; stem cell differentiation [GO:0048863]; thymus development [GO:0048538]; transcription, DNA-templated [GO:0006351] |
Gene Ontology (Molecular Function) Complete annatation | chromatin binding [GO:0003682]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding [GO:0001227] |
Gene Ontology (Cellular Component) Complete annatation | ESC/E(Z complex [GO:0035098]; histone methyltransferase complex [GO:0035097]; nucleoplasm [GO:0005654]; nucleus [GO:0005634] |
Protein-protein interaction | 109923 |
Phylogenetic tree | Q92833 |
HIV replication factor status |
Zhou et al., Cell. Host. Microbe., 2008 unknown Brass et al., Science, 2008 unknown Smith et al., J. Immunol, 2010 unknown |
Interferon-stimulated gene status |
Lu et al., J. Virol., 2011 Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown; Schoggins JW and Rice CM, Curr. Opin. Virol., 2011 Targeted viruses: unknown Viral life cycle: unknown Mechanism related to antiviral activity: unknown |
Anti-viral restriction factor |
Liu et al., Retrovirology, 2011 unknown (Triplicates) |
Up-regulated;
Down-regulated
For brief introduction to each study, please go to the help page.
(1). Mohammadi et al., PLoS Pathog., 2014 Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model DMSO: Dimethyl suloxyde (negative control) - 0.0033% final SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies IL7: Interleukin-7 based stimulation DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM |
|||
Experimental Condition | Log2 Fold Change | P value | Adjusted P value |
AZA vs. CD3 | 1.72107276182956 | 0.00430879623217517 | 0.012814162748884 |
AZA vs. DISU | 0.0075187759516261 | 0.976352108495026 | 0.997866410160284 |
AZA vs. IL7 | 0.0152574188439498 | 0.937059396506618 | 0.999311006273513 |
AZA vs. SAHA | 0.224139885797334 | 0.3596386186775 | 0.727969993009888 |
DISU vs. CD3 | -1.72699204312342 | 0.00478142953446425 | 0.0156007075330117 |
DISU vs. IL7 | -0.00112076727545016 | 0.996455059366594 | 0.999957156847617 |
DISU vs. SAHA | 0.218535578403995 | 0.455227122108446 | 0.795631213881061 |
DMSO vs. AZA | -0.00518773325814268 | 0.975451894180119 | 1 |
DMSO vs. CD3 | -1.73858921236408 | 0.00392132865645389 | 0.0111683150594916 |
DMSO vs. DISU | -0.0147510920070306 | 0.951904811793744 | 0.993524885547521 |
DMSO vs. IL7 | 0.0278406104467229 | 0.877550521373744 | 0.973265104409616 |
DMSO vs. SAHA | 0.222936198483719 | 0.345846746977448 | 0.696918882697836 |
HIV vs. Mock in Activation | 0.395201299056007 | 0.749622755471339 | 0.999983755607037 |
HIV vs. Mock in Latency | -0.119439415971186 | 0.470541472417913 | 0.999834320637052 |
IL7 vs. CD3 | -1.69876077578362 | 0.00504431155423868 | 0.0168849451603463 |
SAHA vs. CD3 | -1.52173347777622 | 0.0112968739050672 | 0.0284641179985558 |
SAHA vs. IL7 | 0.205415381012679 | 0.401291308684857 | 0.64827619624001 |
(2). Iglesias-Ussel et al., J. Virol., 2013 Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model |
|||
Log2 Fold Change | P Value | ||
unknown | unknown |
(1). Imbeault et al., PloS Pathog., 2012 Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells |
|||||
Experiment type | Log2 Fold Change | P Value | Adjusted P Value | ||
Infected vs. Mock | unknown | unknown | unknown | ||
Infected vs. Bystander | unknown | unknown | unknown | ||
(2). Lefebvre et al., J. Virol., 2011 Transcriptome analysis of T-cell line (Sup T1) |
|||||
Log2 Fold Change | unknown | ||||
(3). Li et al., J. Immunol., 2013 Lymphatic tissue |
|||||
Acute Fold Change | Acute P Value | Asymt Fold Change | Asypt P Value | AIDS Fold Change | AIDS P Value |
unknown | unknown | unknown | unknown | unknown | unknown |
(4). Chang et al., MBio., 2011 Transcriptome analysis of T-cell line (Sup T1) Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation |
|||||
Up-regulated (True) | FALSE | ||||
(5). Sherrill-Mix et al., BMC Retrovirol., 2015 Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based |
|||||
Test Status | Log2 Fold Change | P Value | |||
OK | -0.104598 | 0.518172 | |||
(6). Rotger et al., PLoS Pathog., 2010 Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient (Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach) |
|||||
Log2 Fold Change | P Value | ||||
unknown | unknown |
(1). Greenwood et al., Elife, 2016 Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset |
||||||
6 h | 24 h | 48 h | 72 h | RTi | ||
0.939 | 1.655 | 1.478 | 1.295 | 1.699 | ||
(2). Navare et al., Virology, 2012 SUP-T1 cell line |
||||||
FC-4hpi | P-value | FC-8hpi | P-value | FC-20hpi | P-value | Category |
unknown | unknown | unknown | unknown | unknown | unknown | unknown |
(3). Hyrcza et al., J. Virolo., 2007 Primary human CD4+ and CD8+ T Cells |
||||||
Affymetrix Prob ID | Fold Change | In CD8? | Category | |||
unknown | unknown | unknown | unknown |
PDB Accession | Method | Resolution | Chain | Structure Preview |
---|---|---|---|---|
5HYN | X-ray | 2.9Å | E/J/P/U=110-121. | ![]() |
Pathway Accession Number | Description |
---|---|
hsa04550 | Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human) |
|